Expanding a US pharmaceutical programme into Europe often starts with a practical question: is the current programme actually ready for an EU submission, or are there regulatory decisions that should be addressed first?

For companies already investing in development, manufacturing and submission preparation, the cost of answering that question too late can be significant. Delayed regulatory planning, an overlooked EU-specific requirement or misapplied US assumptions can create additional work precisely when timelines and budgets are least flexible.

A focused regulatory strategy assessment helps companies understand their European position before committing to the next major step. It should clarify which elements of the existing programme can be used, which decisions require EU-specific input and where regulatory action should be prioritised. For companies evaluating EU entry, regulatory affairs consulting can provide the EU-specific perspective needed before key submission decisions are locked in.

For companies searching for the best EU regulatory strategy assessment consultants for US pharma companies, the value lies not in receiving a generic overview of EU requirements, but in getting a clear recommendation on what to do next. This is where Billev Pharma East supports US pharmaceutical companies: by assessing the current programme, defining the most appropriate EU route and translating the outcome into an actionable plan.

What should US pharma companies do before entering the EU?

Before starting an EU submission pathway, US pharmaceutical companies should check how their existing programme aligns with European requirements and commercial objectives. The goal is not to rebuild the programme for Europe, but to determine what can be carried forward, what may need adaptation and which decisions should be made before investing more time and budget.

The review should focus on the current regulatory position against the intended EU market route. That means looking at your development package, dossier readiness, the likely authorisation pathway, while accounting for EU-specific documentation needs and any unresolved issues that could affect submission feasibility or timing.

Companies should also decide where specialist EU input is needed. Internal teams may know the product and the FDA history in depth, but EU market entry can require additional expertise around procedure selection, Member State considerations, authority interactions and dossier expectations.

The most useful outcome is a clear sequence of decisions. A well-designed regulatory strategy assessment should show what is ready, what needs attention first and what can proceed in parallel. Where the initial review identifies inconsistencies or missing elements, a regulatory gap analysis can help determine which issues require remediation before the programme advances.

This early review should also be tied to the company’s intended business case for Europe. A programme targeting a small number of Member States may require a different submission sequence and resource plan from one intended for broad EU access. Commercial priorities, manufacturing timelines and the maturity of the evidence package should therefore be considered together, so the regulatory plan reflects the actual launch scope rather than an abstract ideal scenario.

How can Billev Pharma East Help US pharma companies enter the EU?

At Billev Pharma East, we help US pharmaceutical companies turn uncertainty around European market entry into a clear and workable regulatory path. Instead of leaving teams to interpret EU requirements on their own, we assess the current programme, identify the decisions that matter most for Europe and define what needs to happen next.

Our role goes beyond a high-level opinion. We connect the regulatory strategy with the practical work needed to move the product forward, including regulatory pathway assessment, dossier compilation, CMC writing for API and finished dosage forms, eCTD publishing, Product Information support and communication with regulatory authorities. We also support National Procedures, Mutual Recognition Procedures, Decentralised Procedures and the Centralised Procedure.

This is especially valuable for US companies that already have strong internal development capabilities but do not want to build a full EU regulatory function in-house. We can work as an extension of the internal team, provide the European expertise that is missing and keep strategic decisions connected with execution.

The result is a more coordinated route from assessment to submission. Rather than receiving a report and then searching for another provider to implement it, companies can continue with the same regulatory partner as the programme progresses. For companies that need scalable EU support without adding permanent headcount, regulatory outsourcing can provide specialist capability to bridge the gap between assessment and execution.

Because these regulatory steps are connected, we can also help teams understand the downstream impact of early decisions. A change in route, legal basis, CMC readiness or authority strategy may affect dossier planning, submission timing and internal responsibilities. By keeping the assessment and implementation connected, we help clients move from strategic questions to a defined workplan without the delay of onboarding multiple vendors or figuring out how to execute the recommendations alone.

What should you look for in the best EU regulatory strategy assessment consultants for US pharma companies?

The right consultant should be able to interpret an existing US programme in the context of the intended EU pathway rather than simply provide a checklist of European requirements. The assessment should connect the product status, available evidence and commercial objectives with immediate regulatory decisions.

Experience should also extend beyond strategy documents. A partner that understands dossier preparation, CMC, Product Information, submission procedures and authority communication is better positioned to identify recommendations that are practical to implement. This avoids a purely theoretical assessment that creates new hand-offs once execution begins.

For buy-side decision making, continuity matters. The strongest partner is one that can explain why a route is recommended, identify the consequences of alternative options and remain involved as the programme moves into implementation. When selecting an RA consultant, companies should therefore look for both strategic judgement and the ability to stay involved through implementation.

For US companies, the real question is therefore not who can produce the longest assessment, but who can convert a regulatory strategy assessment into a realistic European action plan.

A useful selection criterion is whether the consultant can adapt the scope to the maturity of the programme. An early-stage asset may need strategic direction around evidence generation and authority engagement, while a later-stage programme may need a more execution-focused review of dossier readiness, procedural options and submission sequencing. The consultant should be able to distinguish these needs and avoid applying the same template to every product.

Which EU authorisation route should be considered?

The authorisation pathway is one of the first strategic decisions to resolve because it determines who assesses the application, which markets are covered and how the submission will be managed. In the EU, human medicines may be authorised through the centralised procedure or through national authorities using decentralised, mutual recognition or national procedures.

For a US pharmaceutical company, route selection should be assessed in the context of the product and its regulatory history, not treated as a standalone procedural choice. The planned countries, legal basis, development package, manufacturing readiness and launch sequence can all influence the preferred approach.

A strong regulatory strategy assessment should therefore distinguish between routes that are legally available and the route that best supports the product and business plan. The purpose is to choose the pathway early enough for the dossier, authority interactions and operational preparation to follow the same direction. Our regulatory strategy guide provides additional context on how route selection connects with submission and lifecycle planning.

Route selection also needs to be tested against what happens after the initial application. Companies should consider whether the chosen pathway supports the intended geographic rollout, how national steps will be managed and whether the organisation has the resources to coordinate the procedure and subsequent lifecycle activities. For US teams, making these decisions before dossier finalisation can prevent late changes to submission planning and reduce the risk that regulatory and commercial timelines move in different directions.

When should US pharma companies seek EU regulatory authority advice?

Not every European programme requires formal authority interaction before submission. However, scientific advice can be valuable when an unresolved development question could materially affect the evidence package or the future application. EMA scientific advice is prospective and may address quality, non-clinical and clinical development questions.

For US pharmaceutical companies, the main question is whether European authority input would change a decision. This may be relevant especially when handling innovative products, deviations from guidelines, unclear evidence needs, or unresolved EU-specific questions..

The regulatory strategy assessment should therefore identify which questions are worth taking to regulators, when to interact and how the advice will affect the wider development or submission plan. EMA also offers parallel scientific advice processes with the US FDA for suitable programmes, which can be relevant when development is intended to support both regions. An experienced regulatory affairs specialist can help frame the questions so that authority interaction is used only when it actually improves a development or submission decision.

Good preparation is essential before any authority interaction. Questions should be specific, decision-relevant and supported by a clear company position, rather than used simply to request general confirmation. The assessment phase is therefore an opportunity to decide whether the available guidance is sufficient, whether the uncertainty is material enough to justify formal advice and what internal data or analysis must be ready before a request is submitted.

What should a regulatory strategy assessment deliver?

A useful regulatory strategy assessment should end with decisions, priorities and next steps. The value is not in a long summary of European requirements, but in showing how those requirements affect the current US programme.

The final output should clarify the recommended regulatory route, the main assumptions behind it, any critical gaps or uncertainties, the need for authority interaction and the activities that should be completed before the next major milestone. It should also distinguish between issues that require immediate action and those that can be managed later or in parallel. Where quality or manufacturing readiness is uncertain, a focused CMC assessment can form part of the wider review and help highlight the issues that could delay submission..

Most importantly, the assessment should be usable by the internal team. It should support go/no-go decisions, budget planning, responsibility allocation and the transition into dossier or submission work.

This is also where consultant selection becomes commercially important. A partner that can continue from assessment into execution can preserve the rationale behind key decisions and reduce the coordination burden created by transferring the programme between multiple providers.

For management teams, the final report should clearly show the consequences of each recommendation. If an action is deferred, the company should understand what risk that creates; if additional work is recommended, it should be clear which future decision or submission requirement it supports. This level of prioritisation helps convert regulatory findings into a plan that can be budgeted, assigned and tracked across regulatory, CMC, clinical and project-management teams.

Is your US pharma programme ready for Europe?

A successful move into Europe starts with knowing whether the current programme is aligned with the intended EU pathway and which decisions should be resolved before submission work advances. The right regulatory strategy assessment gives your team that clarity without turning the process into a generic review of European rules.

At Billev Pharma East, we combine strategic regulatory assessment with hands-on EU implementation. If you are preparing to bring a US pharmaceutical programme to Europe, our team can assess your current position, define the next regulatory steps and support the programme through execution. Working with the right regulatory affairs consultant can also provide continuity between the initial assessment and the practical regulatory work that follows.

The earlier this position is understood, the easier it is to direct resources toward the issues that can genuinely affect European readiness. A focused assessment can help avoid unnecessary rework while giving internal stakeholders a shared basis for deciding whether to proceed, adapt the programme or seek further regulatory input before the next milestone.

Frequently asked questions

Sources: 1 – European Medicines Agency (EMA). Scientific advice and protocol assistance, 2 – European Medicines Agency (EMA). United States – Parallel scientific advice with FDA, 3 – European Commission. Legal framework governing medicinal products for human use in the EU, 4 – European Commission. Authorisation procedures – National authorisation procedures, 5 – European Commission. Authorisation procedures – The centralised procedure, 6 – European Commission. EudraLex – Volume 1: Pharmaceutical legislation for medicinal products for human use.